WOMEN 'S HEALTH AND MENOPAUSE : - National Heart, Lung ...

93 Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ.
Estrogen replacement therapy and ovarian cancer
mortality in a large prospective study of US
women. JAMA 2001;285(11):1460–5.
94 Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE,
Liff JM, Daling JR. Noncontraceptive estrogen use
and the occurrence of ovarian cancer. J Natl
Cancer Inst 1982;68(1):95–8.
95 Franceschi S, La Vecchia C, Helmrich SP, Mangioni
C, Tognoni G. Risk factors for epithelial ovarian
cancer in Italy. Am J Epidemiol 1982;115(5):714–9.
96 Tzonou A, Day NE, Trichopoulos D, et al. The epidemiology
of ovarian cancer in Greece: a case-control
study. Eur J Cancer Clin Oncol 1984;20(8):
1045–52.
97 Harlow BL, Weiss, NS, Roth GJ, Chu J, Daling JR.
Case-control study of borderline ovarian tumors:
reproductive history and exposure to exogenous
female hormones. Cancer Res 1988;48(20):5849–52.
98 Kaufman DW, Kelly JP, Welch WR, et al.
Noncontraceptive estrogen use and epithelial ovarian
cancer. Am J Epidemiol 1989;130(6):1142–51.
99 Booth M, Beral V, Smith P. Risk factors for ovarian
cancer: a case-control study. Br J Cancer
1989;60(4):592–8.
100 Polychronopoulou A, Tzonou A, Hsieh C, et al.
Reproductive variables, tobacco, ethanol, coffee
and somatometry as risk factors for ovarian cancer.
Int J Cancer 1993;55(3):402-7.
101 Parazzini F, La Vecchia C, Negri E, Villa A. Estrogen
replacement therapy and ovarian cancer risk (letter).
Int J Cancer 1994;57(10):135–6.
102 Purdie D, Green A, Bain C, et al. Reproductive and
other factors and risk of epithelial ovarian cancer:
an Australian case-control study. Int J Cancer
1995;62(2):678–84.
103 Risch HA, Marrett LD, Jain M, Howe GR.
Differences in risk factors for epithelial ovarian
cancer by histologic type. Results of a case-control
study. Am J Epidemiol 1996;144(4):363–72.
104 Hempling RE, Wong C, Piver MS, Recio FO,
O’Neill CP. Hormone replacement therapy
as a risk factor for epithelial ovarian cancer:
results of a case-control study. Obstet Gynecol
1997;89(6):1012–16.
248
105 Whittemore AS, Harris R, Itnyre J. Characteristics
relating to ovarian cancer risk: collaborative analysis
of 12 US case-control studies. II. Invasive
epithelial ovarian cancers in white women. Am J
Epidemiol 1992;136(10):1184–203.
106 Harris R, Whittemore AS, Itnyre J. Characteristics
relating to ovarian cancer risk: collaborative analysis
of 12 US case-control studies. III. Epithelial
tumors of low malignant potential in White
women. Am J Epidemiol 1992;136(10):1204–11.
107 Purdie D, Bain CJ, Siskind V, et al. Hormone
replacement therapy and risk of epithelial ovarian
cancer. Br J Cancer 1999;81(3):559–63.
108 Negri E, Tzonou A, Beral V, et al. Hormonal therapy
for menopause and ovarian cancer in a collaborative
re-analysis of European studies. Int J Cancer
1999;80(6):848–51.
109 Garg PP, Kerlikowske K, Subak L, Grady D.
Hormone replacement therapy and the risk of
epithelial ovarian carcinoma: A meta-analysis.
Obstet Gynecol 1998;92(3):472–9.
110 McMichael AJ, Giles GG. Colorectal cancer. Cancer
Surv 1994;19-20:77–98.
111 Wu AH, Paganini-Hill A, Ross RK, Henderson BE.
Alcohol, physical activity and other risk factors for
colorectal cancer: a prospective study. Br J Cancer
1987;55(6):687–94.
112 Chute CG, Willett WC, Colditz GA, Stampfer MJ,
Rosner B, Speizer FE. A prospective study of
reproductive history and exogenous estrogens on
the risk of colorectal cancer in women.
Epidemiology 1991;2(3):201–7.
113 Grodstein F, Martinez E, Platz EA, et al.
Postmenopausal hormone use and risk for colorectal
cancer and adenoma. Ann Intern Med
1998;128(9):705–12.
114 Bostick RM, Potter JD, Kushi LH, et al. Sugar, meat,
and fat intake, and non-dietary risk factors for
colon cancer incidence in Iowa women (United
States). Cancer Causes Control 1994;5(1):38–52.
115 Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng
W, Potter JD. Hormonal replacement therapy and
morbidity and mortality in a prospective study of
postmenopausal women. Am J Public Health
1995;85(8Pt1):1128–32.